{"id":149115,"date":"2026-01-20T14:56:07","date_gmt":"2026-01-20T13:56:07","guid":{"rendered":"https:\/\/www.startupbusiness.it\/excivas-alzheimers-treatments-raise-e51-million\/149115\/"},"modified":"2026-01-20T15:50:42","modified_gmt":"2026-01-20T14:50:42","slug":"excivas-alzheimers-treatments-raise-e51-million","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/","title":{"rendered":"Exciva’s Alzheimer’s treatments raise \u20ac51 million"},"content":{"rendered":"\n

Exciva, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric disorders, announces that it has closed a \u20ac51 million Series B financing round. Gimv and EQT Life Sciences co-led the round. Other participants include new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.<\/p>\n\n

The proceeds will primarily be used to fund a Phase 2 study to evaluate the therapeutic potential of Deraphan in treating agitation in patients with Alzheimer’s disease. Deraphan is a combination of two clinically validated products, including a new chemical entity, which have demonstrated activity in the central nervous system, with the potential to offer improved efficacy and a better risk\/benefit ratio than existing therapies. The clinical trial will be conducted in Europe, the United Kingdom, the United States and Canada. A Phase 1 trial with Deraphan has been successfully completed and has demonstrated that the combination is safe and well tolerated. <\/p>\n\n

Following the Series B round, the board of directors will consist of Rapha\u00ebl Wisniewski (Andera Partners), Philip Scheltens (EQT Life Sciences), Andreas Jurgeit (Gimv), Aidan King (Fountain Healthcare), Vikram Sudarsan (independent board member) and Fran\u00e7ois Conquet (CEO).<\/p>\n\n

“We are delighted to have attracted funding from both existing and new investors. This confirms that our product is highly promising,” said Fran\u00e7ois Conquet, CEO of Exciva, in a statement. “If the results of the Phase 2 trial are positive, this will be a significant step forward in symptomatic treatment options for patients with Alzheimer’s disease.”<\/p>\n\n

\u201cExciva\u2019s therapy for agitation in Alzheimer\u2019s disease is highly differentiated and addresses significant gaps in the current standard of care and other products in development,\u201d said Andreas Jurgeit, PhD, partner at Gimv. . “We are delighted to be partnering with the Exciva team, which has decades of experience in developing neuropsychiatric drugs, including approved therapies, to transform the treatment of this challenging aspect of dementia.”<\/p>\n\n

\u201cThis investment demonstrates Exciva\u2019s potential to bring exciting innovation to a therapeutic area where Alzheimer\u2019s patients have limited or no treatment options,\u201d adds Philip Scheltens, MD, PhD, partner at EQT Life Sciences. \u201cWe are delighted to co-lead this financing to realise the potential of Exciva, which stands out both for the quality of its science and the expertise of its team. We look forward to bringing this new therapy to patients.” (photo by Robina Weermeijer<\/a> on Unsplash<\/a>)<\/p>\n","protected":false},"excerpt":{"rendered":"

The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials<\/p>\n","protected":false},"author":125,"featured_media":149105,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1317],"tags":[2236,1143,1321,1136,1145],"companies":[3149],"journalist":[1518],"class_list":["post-149115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-europa-en","tag-investments","tag-lifescience-en","tag-startup-en-2","tag-venture-capital-en-2","companies-exciva-en","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","width":150,"height":84,"crop":false,"srcset":false,"alt":"alzheimer cura"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","width":1024,"height":576,"crop":false,"srcset":false,"alt":"alzheimer cura"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","width":1280,"height":720,"crop":false,"srcset":false,"alt":"alzheimer cura"}},"acf":[],"yoast_head":"\nExciva's Alzheimer's treatments raise \u20ac51 million<\/title>\n<meta name=\"description\" content=\"The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exciva's Alzheimer's treatments raise \u20ac51 million\" \/>\n<meta property=\"og:description\" content=\"The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T13:56:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T14:50:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Exciva’s Alzheimer’s treatments raise \u20ac51 million\",\"datePublished\":\"2026-01-20T13:56:07+00:00\",\"dateModified\":\"2026-01-20T14:50:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/\"},\"wordCount\":407,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp\",\"keywords\":[\"Europa\",\"investments\",\"lifescience\",\"startup\",\"venture capital\"],\"articleSection\":[\"Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/\",\"name\":\"Exciva's Alzheimer's treatments raise \u20ac51 million\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp\",\"datePublished\":\"2026-01-20T13:56:07+00:00\",\"dateModified\":\"2026-01-20T14:50:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/excivas-alzheimers-treatments-raise-e51-million\\\/149115\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp\",\"width\":1280,\"height\":720,\"caption\":\"alzheimer cura\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exciva's Alzheimer's treatments raise \u20ac51 million","description":"The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/","og_locale":"en_US","og_type":"article","og_title":"Exciva's Alzheimer's treatments raise \u20ac51 million","og_description":"The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials","og_url":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/","og_site_name":"Startupbusiness.it","article_published_time":"2026-01-20T13:56:07+00:00","article_modified_time":"2026-01-20T14:50:42+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Exciva’s Alzheimer’s treatments raise \u20ac51 million","datePublished":"2026-01-20T13:56:07+00:00","dateModified":"2026-01-20T14:50:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/"},"wordCount":407,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","keywords":["Europa","investments","lifescience","startup","venture capital"],"articleSection":["Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/","url":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/","name":"Exciva's Alzheimer's treatments raise \u20ac51 million","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","datePublished":"2026-01-20T13:56:07+00:00","dateModified":"2026-01-20T14:50:42+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/excivas-alzheimers-treatments-raise-e51-million\/149115\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/01\/robina-weermeijer-IHfOpAzzjHM-unsplash.webp","width":1280,"height":720,"caption":"alzheimer cura"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Funding News"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/149115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=149115"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/149115\/revisions"}],"predecessor-version":[{"id":149116,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/149115\/revisions\/149116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/149105"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=149115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=149115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=149115"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=149115"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=149115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}